Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 26;13(6):569.
doi: 10.3390/vaccines13060569.

Vaccine Development for Human Pneumoviruses

Elhadji Birane Mboup  1 , Marie-Ève Hamelin  1   2 , Julia Dubois  2   3   4 , Manuel Rosa-Calatrava  2   3   4   5 , Guy Boivin  1   2   5
Affiliations
Review

Vaccine Development for Human Pneumoviruses

Elhadji Birane Mboup et al. Vaccines (Basel). .

Abstract

Background: Pneumoviruses are etiologic agents of respiratory tract infections and a major cause of morbidity and mortality worldwide, particularly affecting young children, the elderly, and individuals with underlying clinical conditions. These viruses are associated with a significant burden, particularly in low- and middle-income countries, where reported deaths attributable to respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) in young children are important. Recent developments have been noted in the prevention of pneumoviral infections.

Method: In this review, we analyzed clinical trials of the approved RSV vaccines, as well as the recent prominent platform technologies used in RSV vaccine research. In addition, we discussed combination vaccines targeting RSV, HMPV, and Human Parainfluenza Virus Type 3 (HPIV3) that have entered clinical trials.

Results: Recent advancements include the approval of three RSV vaccine candidates: AREXVY®(GSK), ABRYSVO®(Pfizer), and mRESVIA®(Moderna). These vaccines are primarily intended for older adults, with ABRYSVO® also capable of providing passive immunization to infants via maternal administration. The review highlights RSV vaccine platform technologies and combination vaccines currently being evaluated in clinical settings.

Conclusions: While significant progress has been made in RSV vaccine development, especially with three approved candidates, the development of vaccines for HMPV remains an unmet medical need. Ongoing research in combination vaccines holds promise for broader protection against multiple respiratory viruses in the future.

Keywords: clinical trial; human metapneumovirus (HMPV); lower respiratory tract infection (LRTI); pneumovirus; respiratory syncytial virus (RSV); vaccine.

PubMed Disclaimer

Conflict of interest statement

G.B., M.R.C., J.D., and M.-È.H. are cofounders and shareholders of Vaxxel.

Figures

Figure 1
Figure 1
Schematic representation of prefusion (A) RSV-F (PDB ID: 8W3P) or (B) postfusion RSV-F (PDB ID: 3RRT); schematic representation of (C) prefusion HMPV-F PDB ID: 7SEJ) or (D) postfusion HMPV-F (PDB ID: 7m0i); genome organization of (E) HMPV or (F) RSV. Created with PyMOL and BioRender.
Figure 2
Figure 2
Pneumoviruses preventive modalities timeline.
See this image and copyright information in PMC

References

    1. Safiri S., Mahmoodpoor A., Kolahi A.A., Nejadghaderi S.A., Sullman M.J.M., Mansournia M.A., Ansarin K., Collins G.S., Kaufman J.S., Abdollahi M. Global burden of lower respiratory infections during the last three decades. Front. Public Health. 2023;10:1028525. doi: 10.3389/fpubh.2022.1028525. - DOI - PMC - PubMed
    1. IHME (Institute for Health Metrics and Evaluation) Global Burden of Disease 2021: Findings from the GBD 2021 Study. IHME; Seattle, WA, USA: 2024.
    1. Li Y., Nair H. Trends in the global burden of lower respiratory infections: The knowns and the unknowns. Lancet Infect. Dis. 2022;22:1523–1525. doi: 10.1016/S1473-3099(22)00445-5. - DOI - PubMed
    1. O’Brien K.L., Baggett H.C., Brooks W.A., Feikin D.R., Hammitt L.L., Higdon M.M., Howie S.R.C., Deloria Knoll M., Kotloff K.L., Levine O.S., et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: The PERCH multi-country case-control study. Lancet. 2019;394:757–779. doi: 10.1016/S0140-6736(19)30721-4. - DOI - PMC - PubMed
    1. Li Y., Wang X., Blau D.M., Caballero M.T., Feikin D.R., Gill C.J., A Madhi S., Omer S.B., Simões E.A.F., Campbell H., et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis. Lancet. 2022;399:2047–2064. doi: 10.1016/S0140-6736(22)00478-0. - DOI - PMC - PubMed

Grants and funding

LinkOut - more resources